Star Combo Pharma Limited (ASX:S66)
Australia · Delayed Price · Currency is AUD 0.2050
-0.0050 (-2.38%)
Mar 4, 2026, 9:59 AM AEST
Star Combo Pharma Income Statement
Financials in millions AUD. Fiscal year is July - June.
Millions AUD. Fiscal year is Jul - Jun.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 |
Operating Revenue | 23.99 | 27.81 | 26.02 | 24.7 | 22.88 | 26.72 |
Other Revenue | - | - | - | - | 0.08 | 0.24 |
| 23.99 | 27.81 | 26.02 | 24.7 | 22.96 | 26.97 | |
Revenue Growth (YoY) | -18.76% | 6.89% | 5.34% | 7.57% | -14.86% | -31.00% |
Cost of Revenue | 18.02 | 21.54 | 20.3 | 19.91 | 18.79 | 23.54 |
Gross Profit | 5.98 | 6.27 | 5.71 | 4.79 | 4.17 | 3.43 |
Selling, General & Admin | 5.88 | 6.51 | 4.84 | 3.79 | 4.54 | 5.09 |
Other Operating Expenses | -5.13 | -5.24 | -0.2 | -0.16 | -0.3 | - |
Operating Expenses | 0.95 | 1.27 | 4.79 | 3.66 | 4.24 | 5.41 |
Operating Income | 5.03 | 5 | 0.92 | 1.12 | -0.06 | -1.98 |
Interest Expense | -0.19 | -0.19 | -0.2 | -0.19 | -0.17 | -0.24 |
Interest & Investment Income | 0.59 | 0.43 | 0.26 | 0.13 | 0.05 | 0.11 |
Currency Exchange Gain (Loss) | 0.03 | 0.08 | 0.01 | -0.05 | 0.05 | -0.05 |
Other Non Operating Income (Expenses) | -0 | -0 | 0 | - | 0 | - |
EBT Excluding Unusual Items | 5.45 | 5.31 | 1 | 1.02 | -0.14 | -2.16 |
Impairment of Goodwill | - | - | - | - | - | -6.34 |
Gain (Loss) on Sale of Assets | - | - | - | - | -0.09 | - |
Asset Writedown | - | - | - | -4.41 | -1.46 | - |
Legal Settlements | - | - | - | -0.06 | - | - |
Other Unusual Items | - | - | - | - | 0.6 | 1.04 |
Pretax Income | 5.45 | 5.31 | 1 | -3.45 | -1.08 | -7.46 |
Income Tax Expense | 0.07 | 0.06 | 0.25 | 0.55 | -0.39 | 0.41 |
Net Income | 5.39 | 5.25 | 0.75 | -4 | -0.7 | -7.88 |
Preferred Dividends & Other Adjustments | 1.27 | 1.27 | - | - | - | - |
Net Income to Common | 4.12 | 3.98 | 0.75 | -4 | -0.7 | -7.88 |
Net Income Growth | 499.75% | 602.32% | - | - | - | - |
Shares Outstanding (Basic) | 135 | 135 | 135 | 135 | 135 | 135 |
Shares Outstanding (Diluted) | 135 | 135 | 135 | 135 | 135 | 135 |
Shares Change (YoY) | -2.39% | - | - | 0.37% | -0.15% | 47.45% |
EPS (Basic) | 0.03 | 0.03 | 0.01 | -0.03 | -0.01 | -0.06 |
EPS (Diluted) | 0.03 | 0.03 | 0.01 | -0.03 | -0.01 | -0.06 |
EPS Growth | 369.90% | 432.75% | - | - | - | - |
Free Cash Flow | 6.04 | 11.55 | -1.76 | -0.85 | -6.76 | -6.93 |
Free Cash Flow Per Share | 0.04 | 0.09 | -0.01 | -0.01 | -0.05 | -0.05 |
Dividend Per Share | 0.004 | 0.004 | 0.004 | - | - | - |
Gross Margin | 24.91% | 22.55% | 21.96% | 19.38% | 18.18% | 12.72% |
Operating Margin | 20.94% | 17.98% | 3.55% | 4.55% | -0.28% | -7.34% |
Profit Margin | 17.16% | 14.31% | 2.87% | -16.21% | -3.03% | -29.20% |
Free Cash Flow Margin | 25.18% | 41.52% | -6.76% | -3.44% | -29.45% | -25.68% |
EBITDA | 6.86 | 6.64 | 1.73 | 1.63 | 0.37 | -1.54 |
EBITDA Margin | 28.59% | 23.86% | 6.65% | 6.59% | 1.59% | -5.70% |
D&A For EBITDA | 1.83 | 1.64 | 0.81 | 0.51 | 0.43 | 0.44 |
EBIT | 5.03 | 5 | 0.92 | 1.12 | -0.06 | -1.98 |
EBIT Margin | 20.94% | 17.98% | 3.55% | 4.55% | -0.28% | -7.34% |
Effective Tax Rate | 1.23% | 1.20% | 25.35% | - | - | - |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.